Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Fischer, Kirsten; Al‐Sawaf, Othman; Bahlo, Jasmin; Fink, Anna‐Maria; Tandon, Maneesh; Dixon, Mark; Robrecht, Sandra; Warburton, Simon; Humphrey, Kathryn; Samoylova, Olga; M. Liberati, A.; Pinilla‐Ibarz, Javier; Opat, Stephen; Sivcheva, Liliya; Le Dû, Katell; Fogliatto, Laura; Utoft Niemann, Carsten; Weinkove, Robert; Robinson, Sue; J. Kipps, Thomas; Böettcher, Sebastian; Tausch, Eugen; Humerickhouse, Rod; Eichhorst, Barbara; Wendtner, Clemens‐Martin; W. Langerak, Anton; Kreuzer, Karl-Anton; Ritgen, Matthias; Goede, Valentin; Stilgenbauer, Stephan; Mobasher, Mehrdad; Hallek, Michael

doi:10.1056/nejmoa1815281

Public

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Published in New England Journal of Medicine • Jun 4, 2019

Authors:

Kirsten Fischer

Othman Al‐Sawaf

Jasmin Bahlo

Abstract

BACKGROUND: The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known. METHODS: In this open-label, phase 3 trial, we investigated fixed-duration ...

Subject

Venetoclax

Obinutuzumab

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!